Background
Pulmonary embolism (PE) represents a major cause of morbidity and mortality in patients with cancer due to their heightened prothrombotic state. Proper anticoagulation is critical to prevent recurrent venous thromboembolism (VTE), but the optimal duration for anticoagulation in cancer-associated acute low-risk PE remains unclear. Extending anticoagulation might reduce recurrent thrombotic events but raises concerns about increased bleeding, especially in a vulnerable oncologic population. This clinical equipoise underpins the ONCO PE trial conducted in Japan, evaluating rivaroxaban treatment duration in this patient group.
